71,279 Shares in Merck & Co., Inc. (MRK) Acquired by Investec Asset Management PTY Ltd

Investec Asset Management PTY Ltd purchased a new stake in Merck & Co., Inc. (NYSE:MRK) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 71,279 shares of the company’s stock, valued at approximately $4,328,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Taylor Wealth Management Partners bought a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at $110,000. Creative Financial Designs Inc. ADV boosted its stake in shares of Merck & Co., Inc. by 155.2% in the 2nd quarter. Creative Financial Designs Inc. ADV now owns 1,832 shares of the company’s stock valued at $111,000 after purchasing an additional 1,114 shares during the last quarter. Clearwater Capital Advisors LLC bought a new stake in shares of Merck & Co., Inc. in the 1st quarter valued at $103,000. SRS Capital Advisors Inc. boosted its stake in shares of Merck & Co., Inc. by 208.4% in the 1st quarter. SRS Capital Advisors Inc. now owns 1,983 shares of the company’s stock valued at $108,000 after purchasing an additional 1,340 shares during the last quarter. Finally, Well Done LLC bought a new stake in shares of Merck & Co., Inc. in the 1st quarter valued at $115,000. Hedge funds and other institutional investors own 72.18% of the company’s stock.

Shares of NYSE MRK opened at $71.46 on Tuesday. The firm has a market cap of $191.27 billion, a P/E ratio of 17.95, a P/E/G ratio of 2.22 and a beta of 0.81. Merck & Co., Inc. has a 12-month low of $52.83 and a 12-month high of $72.42. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.04 and a current ratio of 1.33.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Friday, July 27th. The company reported $1.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.03. The business had revenue of $10.47 billion for the quarter, compared to analyst estimates of $10.28 billion. Merck & Co., Inc. had a net margin of 3.67% and a return on equity of 32.68%. Merck & Co., Inc.’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.01 earnings per share. Equities research analysts predict that Merck & Co., Inc. will post 4.27 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 5th. Shareholders of record on Monday, September 17th were issued a dividend of $0.48 per share. The ex-dividend date was Friday, September 14th. This represents a $1.92 annualized dividend and a yield of 2.69%. Merck & Co., Inc.’s payout ratio is 48.24%.

In other Merck & Co., Inc. news, VP Rita A. Karachun sold 5,000 shares of the company’s stock in a transaction on Thursday, August 2nd. The shares were sold at an average price of $65.01, for a total transaction of $325,050.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Chairman Kenneth C. Frazier sold 228,091 shares of the company’s stock in a transaction on Tuesday, July 31st. The stock was sold at an average price of $65.00, for a total transaction of $14,825,915.00. Following the transaction, the chairman now owns 938,788 shares in the company, valued at approximately $61,021,220. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 929,360 shares of company stock worth $64,370,599. Corporate insiders own 0.32% of the company’s stock.

A number of research firms have recently commented on MRK. Zacks Investment Research raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $80.00 price objective on the stock in a research note on Monday. Bank of America upped their price objective on shares of Merck & Co., Inc. from $70.00 to $74.00 and gave the company a “buy” rating in a research note on Monday, July 30th. Guggenheim initiated coverage on shares of Merck & Co., Inc. in a research note on Monday. They issued a “buy” rating on the stock. BMO Capital Markets reissued a “buy” rating and set a $70.00 target price on shares of Merck & Co., Inc. in a research note on Sunday, July 22nd. Finally, Jefferies Financial Group reissued a “hold” rating and set a $59.00 target price on shares of Merck & Co., Inc. in a research note on Sunday, July 15th. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $68.61.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Recommended Story: Hedge Funds Explained

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply